<DOC>
	<DOCNO>NCT00783107</DOCNO>
	<brief_summary>This randomize , double-blinded , Phase I dose escalation-deescalation protocol ( DEP ) cyclosporine inhalation solution patient Gold Stage III chronic obstructive pulmonary disease . The purpose study evaluate safety effectiveness aerosolize Cyclosporine treat COPD . The specific aim study : 1 . To identify short term ( 28 day ) safety profile CyIS immunotherapy severe COPD ( GOLD III ) patient particular attention airway reactivity infection risk . 2 . To identify pharmacokinetic-pharmacodynamic relationship CyIS use peripheral blood marker adaptive immune response endpoint subject severe COPD ( GOLD III ) treat short-term . Subjects 45 70 year age confirm diagnosis COPD , Gold Stage III , meet study requirement , enrol study . A total 24 subject either sex enrol study . A total 4 subject cohort ( n=6 ) participate protocol .</brief_summary>
	<brief_title>Aerosol Cyclosporine Chronic Obstructive Pulmonary Disease ( COPD )</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<criteria>Age 45 70 year . A confirmed diagnosis COPD , Gold Stage III , use current accept diagnostic criterion , include clinical/laboratory finding , pulmonary function test , appropriate history exclude disorder could explain lung disease . Subjects agree maintain stable medication regimen absence disease flare ECOG performance status 0 , 1 , 2. pCO2 &lt; 45 mm Hg , room air oxyhemoglobin saturation &gt; 85 % A willingness participate portion protocol , include serial bronchoscopy , requisite surveillance , ancillary immunologic study followup visit institution . For woman childbearing age , negative pregnancy test , willingness use two method contraception , abstinence , undergo monthly pregnancy test . Elevated Tcell cytokine gene expression , define baseline value &gt; mean pilot Gold 01 study population one variable ( CD4+IL2 &gt; 23 % , CD8+IFNg &gt; 17 % , CD8+MHC &gt; 6 % , CD8 TGFb ) . An ability willingness provide write informed consent . Three , exacerbation low respiratory disease past year require systemic corticosteroid , one exacerbation require hospitalization past 6 month Intubation COPD , cause respiratory failure past year Use immunosuppressive therapy ( include oral prednisone ) , aerosolized corticosteroid , anytime within three month prior participation Evidence opportunistic infection/colonization airway , i.e. , nonbacterial Use aerosolize corticosteroid inability maintain inhale corticosteroid therapy dose without change study interval Evidence systemic illness include hematologic disorder ( define absolute neutrophil count ( ANC ) &lt; 4000 /mL platelet &lt; 120,000/mL ) , renal insufficiency ( serum creatinine &gt; 2.0 mg/dL ) , cirrhosis , hepatic insufficiency ( total bilirubin , alkaline phosphatase &gt; 1.5 x normal , SGOT , SGPT &gt; 1.2 x normal value ) , coagulopathy ( INR &gt; 1.4 ) , seizure disorder . Evidence systemic abnormal renal function manifest uncontrolled hypertension ( systolic blood pressure &gt; 160mmHg diastolic blood pressure &gt; 90mmHg ) , hyperkalemia ( serum creatinine &gt; 5.0 meq/dl , and/or elevate serum creatinine normal range subject 's age . Evidence coronary artery disease history , e.g. , angina history myocardial infarction within past 12 month , unless correct CABG within &lt; 5 year , asymptomatic since Pregnant breast feeding female woman childbearing potential practice birth control 6 month follow treatment , fertile sexually active male unwilling use contraceptive technique 6 month follow treatment Positive HIV , hepatitis B C serology , another active infection Current past history cancer exclude basal squamous cell skin cancer Undiagnosed pulmonary nodule require diagnostic evaluation Weight loss &gt; 10 % usual body weight past 6 month BMI &lt; 18 Known hypersensitivity allergy propylene glycol , CsA , lidocaine Concurrent enrollment participation within prior month clinical trial Greater 15 % 200 ml reduction FEV1 post test dose propylene glycol administration Known medical psychological condition ( severe personality disorder mental illness ) would permit subject complete trial sign inform consent Autoimmune disorder disorder suspect systemic immune involvement Active smoking history urinary cotinine &gt; 2 . Hypersensitivity midazolam narcotic would allow bronchoscopy sedation</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>Gold Stage III COPD</keyword>
</DOC>